Evidence map›Paper›PMID 37401647›Full record

ArticleCardiovascular research2023

Chronic SIRT1 supplementation in diabetic mice improves endothelial function by suppressing oxidative stress.

Kangmin Yang, Srividya Velagapudi, Alexander Akhmedov, Simon Kraler, Tetiana Lapikova-Bryhinska, Martin O Schmiady, Xiaoping Wu, Leiluo Geng, Giovanni G Camici, Aimin Xu and 1 more

Open access · hybridAbstract read
In one paragraph

Article in Cardiovascular research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
6.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 38 citations in OpenAlex.

  1. Article
  2. Article
  3. The Sirtuin Network: Linking NADDiabetes/metabolism research and reviews · 2026
    Review
  4. Vascular Aging.Circulation · 2026
    Review
  5. [LC3-mediated autophagy promotes the occurrence of diabetic gastroparesis by targeting SIRT1].Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2026
    Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Kangmin YangCenter for Molecular Cardiology, University of Zürich, Wagistrasse 12, 8952 Schlieren, Switzerland.ORCID 0000-0002-8826-1330
Srividya VelagapudiCenter for Molecular Cardiology, University of Zürich, Wagistrasse 12, 8952 Schlieren, Switzerland.ORCID 0000-0002-7211-4141
Alexander AkhmedovCenter for Molecular Cardiology, University of Zürich, Wagistrasse 12, 8952 Schlieren, Switzerland.ORCID 0000-0003-3052-9493
Simon KralerCenter for Molecular Cardiology, University of Zürich, Wagistrasse 12, 8952 Schlieren, Switzerland.ORCID 0000-0002-8245-7287
Tetiana Lapikova-BryhinskaCenter for Molecular Cardiology, University of Zürich, Wagistrasse 12, 8952 Schlieren, Switzerland.
Martin O SchmiadyDepartment of Cardiac Surgery, University Heart Center, University Hospital Zurich, Rämistrasse 100, 8091 Zurich, Switzerland.
Xiaoping WuState Key Laboratory of Pharmaceutical Biotechnology, Department of Medicine and Department of Pharmacology and Pharmacy, The University of Hong Kong, Sassoon Road 21, Pok Fu Lam, 000000 Hong Kong, China.
Leiluo GengState Key Laboratory of Pharmaceutical Biotechnology, Department of Medicine and Department of Pharmacology and Pharmacy, The University of Hong Kong, Sassoon Road 21, Pok Fu Lam, 000000 Hong Kong, China.
Giovanni G CamiciCenter for Molecular Cardiology, University of Zürich, Wagistrasse 12, 8952 Schlieren, Switzerland.
Aimin XuState Key Laboratory of Pharmaceutical Biotechnology, Department of Medicine and Department of Pharmacology and Pharmacy, The University of Hong Kong, Sassoon Road 21, Pok Fu Lam, 000000 Hong Kong, China.ORCID 0000-0002-0668-033X
Thomas F LüscherCenter for Molecular Cardiology, University of Zürich, Wagistrasse 12, 8952 Schlieren, Switzerland.
University of Zurich · CHUniversity of Hong Kong · HKUniversity Hospital of Zurich · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsEnhancing SIRT1 activity exerts beneficial cardiovascular effects. In diabetes, plasma SIRT1 levels are reduced. We aimed to investigate the therapeutic potential of chronic recombinant murine SIRT1 (rmSIRT1) supplementation to alleviate endothelial and vascular dysfunction in diabetic mice (db/db). METHODS AND

resultsLeft internal mammary arteries obtained from patients undergoing coronary artery bypass grafting with or without a diagnosis of diabetes were assayed for SIRT1 protein levels. Twelve-week-old male db/db mice and db/+ controls were treated with vehicle or rmSIRT1 intraperitoneally for 4 weeks, after which carotid artery pulse wave velocity (PWV) and energy expenditure/activity were assessed by ultrasound and metabolic cages, respectively. Aorta, carotid, and mesenteric arteries were isolated to determine endothelial and vascular function using the myograph system.Arteries obtained from diabetic patients had significantly lower levels of SIRT1 relative to non-diabetics. In line, aortic SIRT1 levels were reduced in db/db mice compared to db/+ mice, while rmSIRT1 supplementation restored SIRT1 levels. Mice receiving rmSIRT1 supplementation displayed increased physical activity and improved vascular compliance as reflected by reduced PWV and attenuated collagen deposition. Aorta of rmSIRT1-treated mice exhibited increased endothelial nitric oxide (eNOS) activity, while endothelium-dependent contractions of their carotid arteries were significantly decreased, with mesenteric resistance arteries showing preserved hyperpolarization. Ex vivo incubation with reactive oxygen species (ROS) scavenger Tiron and NADPH oxidase inhibitor apocynin revealed that rmSIRT1 leads to preserved vascular function by suppressing NADPH oxidase (NOX)-related ROS synthesis. Chronic rmSIRT1 treatment resulted in reduced expression of both NOX1 and NOX4, in line with a reduction in aortic protein carbonylation and plasma nitrotyrosine levels.

conclusionsIn diabetic conditions, arterial SIRT1 levels are significantly reduced. Chronic rmSIRT1 supplementation improves endothelial function and vascular compliance by enhancing eNOS activity and suppressing NOX-related oxidative stress. Thus, SIRT1 supplementation may represent novel therapeutic strategy to prevent diabetic vascular disease.

Indexed as

Diabetes Mellitus, ExperimentalAnimalsDietary SupplementsEndothelium, VascularHumansMaleMiceMice, Inbred C57BLNADPH OxidasesNitric Oxide Synthase Type IIIOxidative StressPulse Wave AnalysisReactive Oxygen SpeciesSirtuin 1VasodilationNADPH OxidasesNitric Oxide Synthase Type IIIReactive Oxygen SpeciesSIRT1 protein, humanSirtuin 1Endothelial functionNitric oxideNOX1–NOX4Reactive oxidative speciesSirtuin

Identifiers

PMID37401647
PMCPMC10578911
OpenAlexW4383053860

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.